DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Teduglutide
OtherFDA approvedRx required

Teduglutide

Also known as: Gattex · Revestive
Brands: Gattex · Revestive

GLP-2 analog approved for short bowel syndrome in patients dependent on parenteral nutrition.

A
Grade A
Multiple human RCTs
Human studies28
PubMed citations29
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Recombinant 33-amino-acid GLP-2 analog with alanine-for-glycine substitution at position 2 that resists DPP-4 cleavage, extending half-life. Trophic to intestinal epithelium.

Evidence summary

28
Human studies
29
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

From the FDA label
Source
abdominal paindecreased appetiteinjection site erythemainjection site paininjection site reactioninsomnianauseapancreatitispruritusrashurticariavomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for short bowel syndrome in adults and pediatric patients ≥1 year (Gattex)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07537686Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)Not Yet Recruiting · Phase 2 · Environmental Enteric Dysfunction · n=55NCT05023382Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case Surveillance)Active Not Recruiting · Short Bowel Syndrome · n=250NCT07319832A Multicenter, Retrospective and Prospective, Observational Study to Evaluate the Efficacy and Safety of Subcutaneous Teduglutide in the Treatment of Short Bowel Syndrome (SBS) in Parenteral Nutrition (PN) Dependent Chinese Pediatric Subjects (≥1 Through 17 Years Old)Recruiting · Short Bowel Syndrome (SBS) · n=12NCT07400783Short Bowel Syndrome: Human Intestinal Organoids to Investigate the Different Efficacy of the GLP-2 Analogue Teduglutide in Pediatric Patients With Short Bowel SyndromeRecruiting · N/A · Short Bowel Syndrome (SBS) · n=50NCT05561647Quantitative Testing of Patient and Prescriber Knowledge About GATTEX (Teduglutide) for Injection Safety and Use InformationRecruiting · Short Bowel Syndrome (SBS) · n=600NCT01990040A Prospective, Multi-center Registry for Patients With Short Bowel SyndromeActive Not Recruiting · Short Bowel Syndrome · n=1806NCT03562130A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN)Completed · Phase 4 · Short Bowel Syndrome · n=25NCT06973304An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral SupportRecruiting · Phase 3 · Short Bowel Syndrome · n=13NCT05371028A Non-interventional, Multicentre Retrospective Study of the Effectiveness and Safety of Teduglutide (REVESTIVE®) in Short Bowel Syndrome Patients in CanadaCompleted · Short Bowel Syndrome (SBS) · n=52NCT02954458A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301Completed · Phase 3 · Short Bowel Syndrome · n=61NCT02949362A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003Completed · Phase 3 · Short Bowel Syndrome · n=29NCT05027308A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg FormulationCompleted · Phase 3 · Short Bowel Syndrome · n=3

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 40114026Peng Y, Feng C et al. · GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism (2025)PMID 40129317Lenti MV, Hammer HF et al. · European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption.United European gastroenterology journal (2025)HumanPMID 39986179Joly F, Jezerski D et al. · Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey.Clinical nutrition (Edinburgh, Scotland) (2025)HumanPMID 40097102Reiner J, Mohebali N et al. · Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice.Molecular metabolism (2025)HumanPMID 39662176Sturgeon JP, Mutasa K et al. · Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration.EBioMedicine (2025)HumanPMID 40773292Kudo Y, Miyamoto K et al. · Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome.JCI insight (2025)HumanPMID 39125394Gondolesi GE, Pape UF et al. · Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.Nutrients (2024)HumanPMID 38761162Frau T, El Khatib M et al. · Emerging drugs for the treatment of short bowel syndrome.Expert opinion on emerging drugs (2024)HumanPMID 38663565Sabra HK, Remeih GS et al. · Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2024)HumanPMID 38873891Wales PW, Hill S et al. · Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.Journal of pediatric gastroenterology and nutrition (2024)HumanPMID 37294295Pironi L, Allard JP et al. · Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2024)HumanPMID 39489296Vanuytsel T, Lakananurak N et al. · Real-world experience with glucagon-like peptide 2 analogues in patients with short bowel syndrome and chronic intestinal failure: Results from an international survey in expert intestinal failure centers.Clinical nutrition ESPEN (2024)HumanPMID 37889619Fifi A, Raphael BP et al. · Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.Journal of pediatric gastroenterology and nutrition (2023)HumanPMID 37364133Chiba M, Masumoto K et al. · Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.Journal of pediatric gastroenterology and nutrition (2023)HumanPMID 37270286Oliveira SB, Kocoshis SA · Teduglutide for the treatment of short bowel syndrome: a double-edged sword?The American journal of clinical nutrition (2023)HumanPMID 37115031Pironi L · Definition, classification, and causes of short bowel syndrome.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2023)HumanPMID 37409717Campos Martín C, Tejera Pérez C et al. · [Review of real-life teduglutide experience].Nutricion hospitalaria (2023)HumanPMID 36263764Pérez-Robles R, Salmerón-García A et al. · Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS.Analytical methods : advancing methods and applications (2022)HumanPMID 36152491Pérez-Robles R, Hermosilla J et al. · Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.Journal of pharmaceutical and biomedical analysis (2022)HumanPMID 32406744Martínez Martínez AL, Calles Romero LA et al. · [Is there life after teduglutide?].Nutricion hospitalaria (2021)Human

Showing 20 of 29 papers. View all on PubMed →